Arbutus Biopharma Logo
Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
December 01, 2021 11:58 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors
November 11, 2021 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®
November 10, 2021 16:30 ET | Arbutus Biopharma Corporation
Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to 28 weeks after discontinuation of AB-729 ...
Arbutus Biopharma Logo
Arbutus to Participate at Jefferies London Healthcare Conference
November 10, 2021 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 04, 2021 07:30 ET | Arbutus Biopharma Corporation
 On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021         First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFNα-2a and nucleos(t)ide analog (“NA”) therapy ...
Arbutus Biopharma Logo
Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021
November 01, 2021 16:05 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
October 21, 2021 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus to Participate in October Investor Conferences
September 28, 2021 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
September 21, 2021 07:30 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...
Arbutus Biopharma Logo
Arbutus to Participate in Upcoming Investor Conferences
September 07, 2021 08:00 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and...